Oct 9, 2026, 9:00 AM EDT · 21 days ago HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
2026-10-02T20:40:11.000Z · 27 days ago HCW Biologics registers to sell 1.81M shares of common stock for holders
2026-09-24T12:45:33.000Z · 5 weeks ago HCW Biologics prices 903,614 units at $1.6599 in private placement
Sep 24, 2026, 8:25 AM EDT · 5 weeks ago HCW Biologics Announces Pricing of $1.5 Million Private Placement
2026-09-08T13:20:17.000Z · 7 weeks ago HCW Biologics enters exclusive HCW11-006 distribution pact with Akron Biotech
Sep 8, 2026, 8:50 AM EDT · 7 weeks ago HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
2026-09-02T13:20:22.000Z · 1 month ago HCW Biologics receives patent allowance for alopecia areata drug
Sep 2, 2026, 9:00 AM EDT · 1 month ago HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
Aug 25, 2026, 9:00 AM EDT · 2 months ago HCW Biologics' TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
2026-08-20T19:05:21.000Z · 2 months ago HCW Biologics files to sell 1.24M shares of common stock for holders
Aug 14, 2026, 3:15 PM EDT · 2 months ago HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
Jul 29, 2026, 9:06 AM EDT · 3 months ago HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
Jul 23, 2026, 8:00 AM EDT · 3 months ago HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027
Jun 30, 2026, 8:25 AM EDT · 4 months ago HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
Jun 26, 2026, 8:55 AM EDT · 4 months ago HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
2026-06-16T11:13:07.000Z · 4 months ago HCW Biologics announces data from first two dose cohorts of HCW9302 trial
Jun 16, 2026, 7:00 AM EDT · 4 months ago HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata
2026-06-08T14:26:45.000Z · 4 months ago HCW Biologics registers to sell 5.69M shares of common stock for holders
May 27, 2026, 7:45 AM EDT · 5 months ago HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
May 22, 2026, 4:02 PM EDT · 5 months ago E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement
May 21, 2026, 9:53 AM EDT · 5 months ago HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
May 14, 2026, 4:25 PM EDT · 5 months ago HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
2026-05-14T14:02:07.000Z · 5 months ago HCW Biologics discovers HCW11-040 prevents bronchopulmonary dysplasia
May 14, 2026, 7:30 AM EDT · 5 months ago HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies
Apr 30, 2026, 4:20 PM EDT · 6 months ago HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
Apr 27, 2026, 7:30 AM EDT · 6 months ago HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
Mar 31, 2026, 5:05 PM EDT · 7 months ago HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
Mar 17, 2026, 7:50 AM EDT · 7 months ago HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
Mar 16, 2026, 8:00 AM EDT · 7 months ago HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances
Mar 2, 2026, 8:00 AM EST · 8 months ago HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter
Feb 17, 2026, 9:50 PM EST · 8 months ago HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
Feb 13, 2026, 8:30 AM EST · 8 months ago HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune
Nov 18, 2025, 7:25 AM EST · 11 months ago HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease
Nov 14, 2025, 4:44 PM EST · 11 months ago HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results
Nov 7, 2025, 7:00 AM EST · 11 months ago HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
Sep 30, 2025, 8:45 AM EDT · 1 year ago HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program
Sep 18, 2025, 9:15 AM EDT · 1 year ago HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing
Sep 16, 2025, 8:00 AM EDT · 1 year ago HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development
Aug 25, 2025, 8:00 AM EDT · 1 year ago HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market
Aug 18, 2025, 2:44 PM EDT · 1 year ago HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results
Jun 27, 2025, 7:45 AM EDT · 1 year ago HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors
Jun 26, 2025, 7:55 AM EDT · 1 year ago HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements
Jun 4, 2025, 8:20 AM EDT · 1 year ago HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech
May 15, 2025, 6:14 PM EDT · 1 year ago HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results
May 13, 2025, 8:01 PM EDT · 1 year ago HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
May 13, 2025, 8:30 AM EDT · 1 year ago HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization
Mar 28, 2025, 3:30 PM EDT · 1 year ago HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results
Mar 6, 2025, 6:55 AM EST · 1 year ago HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements
Feb 3, 2025, 7:15 AM EST · 1 year ago HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
Jan 15, 2025, 7:00 AM EST · 1 year ago HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025
Nov 18, 2024, 9:27 PM EST · 1 year ago HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules
Nov 18, 2024, 7:00 AM EST · 1 year ago HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
Nov 14, 2024, 4:40 PM EST · 1 year ago HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
Aug 23, 2024, 4:30 PM EDT · 2 years ago HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
Aug 14, 2024, 4:35 PM EDT · 2 years ago HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights